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Transcatheter Aortic Valve Replacement
With the Medtronic CoreValve System
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ADVANCE-II StudyAnna S. Petronio, MD,* Jan-Malte Sinning, MD,y Nicolas Van Mieghem, MD,z Giulio Zucchelli, MD, PHD,*
Georg Nickenig, MD,y Rafﬁ Bekeredjian, MD, PHD,x Johan Bosmans, MD, PHD,k Francesco Bedogni, MD,{
Marian Branny, MD,# Karl Stangl, MD,** Jan Kovac, MD,yy Molly Schiltgen, MS,zz Stacia Kraus, MPH,xx
Peter de Jaegere, MD, PHDyABSTRACTOBJECTIVES The aim of the CoreValve prospective, international, post-market ADVANCE-II study was to deﬁne the
rates of conduction disturbances and permanent pacemaker implantation (PPI) after transcatheter aortic valve replace-
ment with the Medtronic CoreValve System (Minneapolis, Minnesota) using optimized implantation techniques and
application of international guidelines on cardiac pacing.
BACKGROUND Conduction disturbances are a frequent complication of transcatheter aortic valve replacement.
The rates of PPI in the published reports vary according to bioprosthesis type and the indications for PPI.
METHODS The primary endpoint was the 30-day incidence of PPI with Class I/II indications when the Medtronic
CoreValve System was implanted at an optimal depth (#6 mm below the aortic annulus). The timing and resolution of
all new-onset conduction disturbances were analyzed.
RESULTS A total of 194 patients were treated. The overall rate of PPI for Class I/II indications was 18.2%. An optimal
depth was reached in 43.2% of patients, with a nonsigniﬁcantly lower incidence of PPI in patients with depths #6 mm,
compared with those with deeper implants (13.3% vs. 21.1%; p ¼ 0.14). In a paired analysis, new-onset left bundle branch
block and ﬁrst-degree atrioventricular block occurred in 45.4% and 39.0% of patients, respectively, and resolved
spontaneously within 30 days in 43.2% and 73.9%, respectively. In patients with new PPI, the rate of intrinsic sinus
rhythm increased from 25.9% at 7 days to 59.3% at 30 days (p ¼ 0.004).
CONCLUSIONS Optimal Medtronic CoreValve System deployment and adherence to international guidelines on cardiac
pacing are associated with a lower rate of new PPI after transcatheter aortic valve replacement, compared with results
reported in previous studies. (CoreValve Advance-II Study: Prospective International Post-Market Study [ADVANCE II];
NCT01624870) (J Am Coll Cardiol Intv 2015;8:837–46) © 2015 by the American College of Cardiology Foundation.
ABBR EV I A T I ON S
AND ACRONYMS
AV = atrioventricular
CD = conduction disturbances
CI = conﬁdence interval
ECG = electrocardiogram
ESC = European Society of
Cardiology
IV = interventricular
LBBB = left bundle branch
block
MCS = Medtronic CoreValve
System
MSCT = multislice computed
tomography
MVP = managed ventricular
pacing
PPI = permanent pacemaker
implantation
TAVR = transcatheter aortic
valve replacement
TTE = transthoracic
echocardiography
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838T ranscatheter aortic valve replace-ment (TAVR) is now an establishedand safe therapy for patients with
aortic stenosis who are at high risk for surgi-
cal aortic valve replacement (1,2). Conduc-
tion disturbances (CD) requiring permanent
pacemaker implantation (PPI) frequently
occur following implantation of the self-
expanding Medtronic CoreValve System
(MCS) (Medtronic Inc., Minneapolis, Minne-
sota). However, the reported rate of PPI
varies widely, ranging from 10% to 47%
(3–7). Although improvement in operator
skill has led to a consistent reduction in the
occurrence of such complications, the vari-
ability in PPI rates persists. This is most likely
due to varying criteria underlying pacemaker
implantation decisions and lack of consensus
on the treatment strategy for CD after TAVR.SEE PAGE 847The purpose of ADVANCE II (the CoreValve
Prospective International Post-Market Advance II
Study) was to evaluate the rate of new PPI according
to Class I or II indications as recommended by the
European Society of Cardiology (ESC) (8) when the
MCS was optimally deployed at a depth of #6 mm
below the aortic annulus. In addition, we assessed the
rate of new-onset CD and the time course of their
resolution, as well as the safety and efﬁcacy outcomes
associated with the TAVR procedure.
METHODS
POPULATION. Patients undergoing TAVR for symp-
tomatic aortic stenosis and treated with the MCS were
prospectively enrolled after heart team evaluation.Cardiothoracic and Vascular Department, Azienda Ospedaliero U
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consistent with manufacturer recommendations. Pa-
tients with a pre-existing device that regulated heart
rhythm, as well as patients with pre-existing class I or
II indications for a new PPI according to the 2007 ESC
guidelines were not eligible. Persistent and perma-
nent atrial ﬁbrillation were also exclusion criteria as
these conditions preclude accurate assessment of
new-onset conduction disturbances.
PROCEDURAL DETAILS. All patients underwent
TAVR with CoreValve and the 18-F delivery system
with the AccuTrak Stability Layer as previously des-
cribed (1). Valve size was selected based on annular
perimeter measurements that were obtained from
multislice computed tomography (MSCT) prior to the
TAVR procedure. Device oversizing was calculated as
follows: [(perimeter of the prosthesis – MSCT derived
perimeter of the annulus) / MSCT derived perimeter
of the annulus)  100].
All centers were asked to comply with the
following recommendations: 1) balloon valvuloplasty
using an undersized straight balloon; 2) temporary
high-frequency pacing during balloon valvuloplasty;
3) a waiting period $3 days prior to PPI if clinically
justiﬁed; 4) PPI based on Class I or II 2007 ESC
guidelines as determined by 12-lead surface electro-
cardiogram (ECG); and 5) use of pacemakers with the
managed ventricular pacing (MVP) feature (or similar)
and the ability to provide rhythm analysis reports.
MVP was intended to promote intrinsic conduction,
thereby allowing the pacemaker to be programmed to
minimize unnecessary ventricular pacing.
IMPLANT DEPTH. Implant depth was deﬁned as the
maximal distance (millimeters) between the intra-
ventricular end of the bioprosthesis and the aortic
annulus at the level of the noncoronary cusp, as
measured by angiography in the projection chosenniversitaria Pisana, Pisa, Italy; yDepartment of Med-
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TABLE 1 Baseline Patient Characteristics (N ¼ 200)
Age, yrs 80.2  6.7
STS predictive risk of mortality score, % 7.2  6.8
Logistic EuroSCORE II, % 9.0  8.9
New York Heart Association class III or IV 148/199 (74.4)
Diabetes mellitus 62/200 (31.0)
Coronary artery disease 120/199 (60.3)
Previous myocardial infarction 30/199 (15.1)
Previous coronary artery bypass graft 31/199 (15.6)
Cerebrovascular disease 30/198 (15.2)
Aortic aneurysm 4/199 (2.0)
Peripheral vascular disease 55/199 (27.6)
Chronic obstructive pulmonary disease 42/199 (21.1)
Renal failure 3/200 (1.5)
Atrial ﬁbrillation 21/200 (10.5)
Hypertension 154/199 (77.3)
Previous porcelain aorta 4/191 (2.1)
Hyperlipidemia 92/194 (47.4)
Values are mean  SD or n/N (%).
EuroSCORE ¼ European System for Cardiac Operative Risk Evaluation;
STS ¼ Society of Thoracic Surgeons.
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839for deployment. Implant depth was measured during
the procedure by the operator and off-line by an in-
dependent core laboratory (Cardialysis, Rotterdam,
the Netherlands). “Correct implantation” was de-
ﬁned as a depth #6 mm below the annulus plane,
and a depth >6 mm was considered to be a low
implantation.
ECG DATA COLLECTION. Twelve-lead ECG recor-
dings were obtained before and immediately after
TAVR and at 7 and 30 days of follow-up. Traces were
examined by a core laboratory (Cardialysis) for rate
and rhythm using the criteria of the World Health
Organization and International Society and Federa-
tion for Cardiology Task Force (9).
ECHO DATA COLLECTION. Transthoracic echocardi-
ography (TTE) was performed prior to TAVR and at
days 7 and 30 post-TAVR. Images were examined by
the core laboratory (Cardialysis). Paravalvular leak
was determined according to VARC-1 (Valvular Aca-
demic Research Consortium-1) criteria (10).
STUDY DESIGN AND ENDPOINTS. The ADVANCE II
study was a prospective, multicenter, observational
study performed in 9 high-volume European centers.
The primary endpoint was the incidence of new-onset
Class I or Class II indications for PPI (including sinus
node disease, acquired atrioventricular (AV) block,
and bifascicular/trifascicular block) according to ESC
guidelines at 30 days post-procedure in patients with
a MCS implanted at a depth of #6 mm below the
aortic annulus. An independent advisory committee
consisting of 3 electrophysiologists adjudicated the
indication for all PPI.
Secondary endpoints included: 1) evaluation of
safety outcomes according to VARC-2 (11) deﬁni-
tions adjudicated by an independent clinical events
committee; 2) characterization of CD by 12-lead ECG
before TAVR, post-procedure, and at 7 and 30 days
post-TAVR; 3) exploration of the determinants of
AV and interventricular (IV) conduction abnormal-
ities; and 4) determining the frequency of pacing
and pacemaker dependency in patients with a
new PPI, assessed at 30 days using pacemaker
interrogation.
The ethics committee at each center approved the
study protocol, and written informed consent was
obtained from all patients. The study was conducted
in accordance with the Declaration of Helsinki. The
study was designed and funded by Medtronic Inc.
STATISTICAL METHODS. Continuous variables are
reported as mean  SD, mean  SE, and median and
interquartile range, where appropriate. Categorical
variables are reported as frequencies and percentages.PPI rates and other outcome rates were calculated
using Kaplan-Meier analysis. For patients without an
event, the date of censoring was the latest date of all
follow-up visits (including study exit) and events
(including death). Corresponding 2-sided 95% conﬁ-
dence intervals (CIs) were constructed using the
Peto standard error. Thirty-day PPI Kaplan-Meier
rates were compared between implant depth groups
(#6 mm vs. >6 mm) using a z test. Implant depth and
percentage of oversizing comparisons were based on
pooled Student t tests, and post-dilation percentages
were compared using Fisher exact tests. McNemar test
was used to compare paired data of new-onset left
bundle branch block (LBBB) and ﬁrst-degree AV block
between baseline versus 7 days post-implantation,
and 7-days versus 30-days post-implantation. Cox
regression models were used to determine signiﬁcant
predictors of PPI. Univariable predictors of PPI with a
p value <0.20 were entered in the multivariable
model. Receiver operating curves were derived to
assess the predictive value of implant depth on PPI.
The trend of implant depth groups by valve size was
tested using a Cochran-Armitage trend test. Changes
in intrinsic rate percentages from 7 to 30 days were
based on generalized estimating equations account-
ing for repeated measures for patients with paired
data, and the changes in percentage of ventricular
pacing were tested using a signed rank test to account
for the non-normality of the values. All analyses were
performed using SAS software (version 9.3, Cary,
North Carolina).
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840RESULTS
DEMOGRAPHIC AND BASELINE CHARACTERISTICS.
Between October 13, 2011 and April 16, 2013, 200 pa-
tients were enrolled, which represented approxi-
mately 65% of the total number of patients treated
with the MCS in the participating centers. The de-
mographic and clinical characteristics are described
in Table 1. The mean age of the population was 80.2 
6.7 years and the mean Society of Thoracic Surgeons
score was 7.2  6.8. Most of the patients were in New
York Heart Association class III or IV (74.4%).
AV conduction was normal in 75.8% of patients,
whereas IV conduction was normal in 76.8%. TTE
showed the mean aortic valve area to be 0.8  0.2 cm2
and the mean gradient 42.4  14.4 mm Hg, with a
preserved left ventricular ejection fraction in 53.7% of
the population. Imaging and ECG parameters are
summarized in Table 2.
PROCEDURAL CHARACTERISTICS. Of 200 patients
enrolled, 6 did not receive a MCS bioprosthesis (1
patient refused implantation, 3 were reassigned to
AVR, 1 received a new PPI after enrollment but beforeTABLE 2 Baseline Imaging and ECG Characteristics (N ¼ 200)
Electrocardiogram
PQ interval, ms 186.6  39.3 (190)
Normal AV conduction 144/190 (75.8)
First-degree AV block 46/190 (24.2)
Normal IV conduction 152/198 (76.8)
LBBB 11/198 (5.6)
RBBB 12/198 (6.1)
LAFB 21/198 (10.6)
LPFB 1/198 (0.5)
Transthoracic echocardiography
Effective oriﬁce area, cm2 0.8  0.2 (171)
Mean gradient, mm Hg 42.4  14.4 (180)
Aortic annulus diameter, mm 24.5  2.0 (179)
Aortic regurgitation, moderate or severe 32/184 (17.4)
Mitral regurgitation, moderate or severe 20/184 (10.9)
LVEF >55% 94/175 (53.7)
Multislice computer tomography
Aortic annulus perimeter, mm 76.8  6.4 (179)
Patients implanted with the 23-mm valve 68.3  2.5 (5)
Patients implanted with the 26-mm valve 72.3  4.5 (53)
Patients implanted with the 29-mm valve 78.4  5.1 (94)
Patients implanted with the 31-mm valve 83.3  6.6 (22)
Perimeter-derived aortic annulus diameter, mm 24.5  2.0 (179)
Aortic annulus area, mm2 452.2  77.3 (179)
Aortic leaﬂet calcium, mm3 611.2  479.1 (163)
Aortic root angulation, degrees 33.4  8.4 (174)
Values are mean  SD (n) or n/N (%).
AV ¼ atrioventricular; ECG ¼ electrocardiogram; IV ¼ interventricular;
LBBB ¼ left bundle branch block; LAFB ¼ left anterior fascicular block; LPFB¼ left
posterior fascicular block; LVEF ¼ left ventricular ejection fraction; RBBB ¼ right
bundle branch block.treatment, and 1 was treated with a different TAVR
prosthesis). Between implantation and day 30, 5 pa-
tients had died, 1 patient withdrew consent, and 5
patients missed their 30-day follow-up visit. There-
fore, 183 of the 194 implanted patients were available
for 30-day follow-up.
Valve sizing was based on MSCT measurements in
89.7% of the patients and on TTE in the remaining
10.3%. The following MCS sizes were implanted:
23 mm in 2.6%, 26 mm in 29.9%, 29 mm in 55.2%, and
31 mm in 12.4% of patients. Transfemoral access was
used in 89.7% of the procedures, whereas 6.2% and
4.1% of the procedures were from the subclavian and
direct aortic approach, respectively. Aortic valve pre-
dilation was performed in 96.4% of patients, using a
straight balloon in 73.3%, whereas post-dilation was
performed in 22.2%. Two valves were implanted in
7.7% of patients (valve-in-valve in 2.1% and emboli-
zation of the ﬁrst valve into the aorta in 5.7%).
Core lab-assessed implant depth measurements
were available in 192 of the treated patients. The
mean depth of implantation in the overall population
was 6.9  4.3 mm. The target depth of #6 mm was
reached in 83 patients (43.2%), and the mean im-
plantation depth in this group was 3.0  2.2 mm. The
target was not reached in 109 patients (56.8%), and
the mean implant depth was 9.9  2.8 mm.
PRIMARY ENDPOINT AND NEW CONDUCTION
DISTURBANCES. The overall 30-day Kaplan-MeierTABLE 3 Safety Outcomes at 30 Days
All-cause mortality* 1.6 (3) (0.4–4.2)
Myocardial infarction*† 0.5 (1) (0.0–2.7)
Stroke*† 2.1 (4) (0.7–4.9)
Cardiovascular mortality*† 1.6 (3) (0.4–4.2)
Life-threatening or disabling bleeding*† 4.1 (8) (1.9–7.7)
Vascular complications*† 23.2 (45) (17.5–29.5)
Major 11.9 (23) (7.8–16.9)
Minor 12.4 (24) (8.2–17.5)
Acute kidney injury (stage III)*† 0.5 (1) (0.0–2.7)
Pacemaker implantation*† 24.4 (47) (18.6–30.7)
Paravalvular leak, moderate or severe*‡ 8.5 (10) (3.5–13.6)
VARC-2 device success§ 73.6 (114/155)
Absence of procedural mortality 100 (194/194)
Correct position of 1 valve in the
proper location
92.3 (179/194)
Mean gradient <20 mm Hg or peak
velocity <3 m/s
99.4 (173/174)
Absence of moderate or severe
regurgitation
90.2 (156/173)
Absence of patient prosthesis mismatch 89.2 (141/158)
Implanted patients, n ¼ 194. *Kaplan-Meier rates are reported with n (95%
conﬁdence intervals). †Kaplan-Meier rates deﬁned according to the VARC-2 (Valve
Academic Research Consortium-2) deﬁnitions. ‡Calculated as a percentage of
117 patients with echocardiograms available at 30 days. §Rate presented as a
percentage and n/n patients available for each component.
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841rate of new PPI with Class I/II indications according to
the guidelines was 18.2% (n ¼ 35). An acquired AV
block was the main indication for PPI (34 of 35;
97.1%). Twelve patients received a permanent pace-
maker without a Class I/II indication as adjudicatedFIGURE 1 Categorization of PPI
(A) Flow chart describing how patients with permanent pacemaker impl
curves for 30-day permanent pacemaker rates in patients with known imby the independent advisory committee, bringing the
total PPI rate to 24.4% (Table 3). Within the subgroup
of patients with available implant depth (n ¼ 192),
the rate of PPI with class I/II indications was 17.8%
(n ¼ 34, 1 patient with a Class I/II indication wasantations (PPI) were categorized within the study. (B) Kaplan-Meier
plant depths (n ¼ 192).
TABLE 4 Incidence and Timing of CD
Visit* LBBB RBBB LAFB LPFB First-Degree AV Block Third-Degree AV Block
Baseline 11/192 (5.7) 12/192 (6.3) 21/192 (10.9) 1/192 (0.5) 45/185 (24.3) 0/185 (0.0)
Post-TAVR 85/169 (50.3) 13/169 (7.7) 18/169 (10.7) 1/169 (0.6) 57/156 (36.5) 2/156 (1.3)
24 h 83/169 (49.1) 7/169 (4.1) 12/169 (7.1) 0/169 (0.0) 53/155 (34.2) 2/155 (1.3)
48 h 70/147 (47.6) 8/147 (5.4) 8/147 (5.4) 0/147 (0.0) 56/128 (43.8) 4/128 (3.1)
7 days 74/149 (49.7) 6/149 (4.0) 12/149 (8.1) 0/149 (0.0) 67/135 (49.6) 0/135 (0.0)
30 days 43/135 (31.9) 8/135 (5.9) 14/135 (10.4) 0/135 (0.0) 43/127 (33.9) 0/127 (0.0)
Values are n events of n interpretable ECG at the given time point, followed by percentages. *Available 12-lead ECG data at each visit.
CD ¼ conduction disturbance; TAVR ¼ transcatheter aortic valve replacement; other abbreviations as in Table 2.
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842missing implant depth). The rate of PPI for Class I/II
indications in patients with implantation of the MCS
at a depth #6 mm was 13.3% (n ¼ 11). In patients with
low implantation >6 mm, the PPI rate with Class I/II
indications was 21.4% (n ¼ 23) (Figure 1).
Of the 35 patients with a Class I/II indication for PPI
regardless of implant depth, 34 were implanted dur-
ing the index hospital stay. Importantly, no episodes
of third-degree AV block or sudden death occurred
between discharge and 30 days post-TAVR.
The timing of new-onset CD is described in Table 4.
The most frequent CD were new LBBB and ﬁrst-
degree AV block. According to a paired analysis in
patients with normal conduction at baseline and an
available ECG at post-procedure (within 48 h), day 7,
and day 30 (n ¼ 97 for LBBB, n ¼ 59 for ﬁrst-degree AVlution With Time
nts with new-onset left bundle branch block (LBBB) or new-onset
tricular (AV) block at post-procedure, day 7, and day 30 are shown.
ally signiﬁcant decrease in both types of conduction disturbance (CD)
ure and day 7, and between day 7 and day 30. Patients with normal
ion were considered for new-onset AV block. Patients with normal
n were considered for new-onset LBBB. New-onset is deﬁned as a
urbance which initiates within 48 h of TAVR. Patients receiving new
ers were excluded. Paired data for each type of conduction distur-
1st degree n ¼ 59. TAVR ¼ transcatheter aortic valve replacement.block), LBBB and ﬁrst-degree AV block resolved by 30
days in 43.2% and 73.9%, respectively, as shown in
Figure 2.
New Class I/II PPI at 30 days and all new CD were
signiﬁcantly associated with low MCS implantation
(Figure 3). No relation was observed between new CD
and oversizing, which was observed in 10.9% (n ¼ 19)
of patients with available MSCT data. Similarly, post-
dilation was not related to any CD.
The only independent predictor of new PPI for
Class I/II indications at 30 days by multivariable
analysis was implantation depth (hazard ratio:
1.12 per 1 mm depth increase; 95% CI: 1.04 to 1.22;
p ¼ 0.005).
By receiver operating curve analysis, an implanta-
tion depth of <4 mm, which was achieved in 25.5% of
the patients, was found to have the best negative
predictive value (93.9%) for new PPI, although the
positive predictive value was only 21.7% (sensitivity
91.2%, speciﬁcity 29.1%).
Finally, smaller MCS bioprosthesis size was asso-
ciated with a higher rate of optimal implantation
depth, which decreased from 80% to 51.7%, 41.0%,
and 25.0% for the 23-, 26-, 29-, and 31-mm valve sizes,
respectively (p ¼ 0.008) (Figure 4).
Interrogation of pacemakers implanted for Class
I/II indications regardless of implant depth showed
that the rate of available intrinsic rhythm, evaluated
via transient VVI programming at 30 beats/min,
signiﬁcantly increased from 25.9% at 7 days to 59.3%
at 30 days (p ¼ 0.004). We also observed a trend of
reduced ventricular pacing time from 7 to 30 days
(from 90.7  24.1% to 80.8  32.8%, p ¼ 0.135).
An MVP algorithm was available at the 7-day inter-
rogation in 64.3% of patients and activated in 66.7%
of them, whereas at 30-day follow-up, it was available
in 56.3% of patients and activated in 50.0% of them.
A trend toward a reduction in the activation of MVP
was observed between 7- and 30-day follow-up,
whereas no signiﬁcant change was observed in other
parameters.
FIGURE 3 Relationship Between Depth of Implantation and New CD
Patients with new LBBB, ﬁrst-degree AV block, PPI, and third-degree AV block had signiﬁcantly deeper valve implants than those patients
without new CD or PPI. Pooled t test p values, standard error is shown as error bars. New pacemaker at 30 days, new conduction disturbance is
deﬁned as a conduction disturbance not present at baseline which developed within 30 days of TAVR. 3rd degree AV block data from CEC
adjudication, LBBB and 1st degree AV block from core lab adjudication. Implant depth deﬁned as the distance from the lower edge of the
non-coronary leaﬂet to the ventricular edge of the frame. CEC ¼ clinical events committee; other abbreviations as in Figures 1 and 2.
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843ACUTE AND 30-DAY OUTCOMES
The 30-day Kaplan-Meier rates of adverse events
were as follows: all-cause mortality and cardiovas-
cular mortality 1.6%; stroke 2.1%; life-threatening
or disabling bleeding 4.1%; major vascular compli-
cations 11.9%; myocardial infarction 0.5%; and
acute kidney injury (stage III) 0.5%. Paravalvular
leak was moderate or severe in 8.5% of patients and
mild or less in 91.5%. These data are summarized in
Table 3.
DISCUSSION
This is the ﬁrst observational TAVR study with pro-
spectively applied best implantation practices,
rigorous data collection, and independent core labo-
ratory analysis of all imaging and electrocardio-
graphic data. Moreover, the acute and 30-day results
showed a very low rate of major adverse cardiac and
cerebrovascular events, in agreement with the most
recent randomized TAVR trial with the MCS (1).
The close anatomic relationship between the aortic
valve and some of the components of the cardiac
conduction system explains the frequent occurrence
of CD after interventions on the aortic valve. The MCS
bioprosthesis contains of a self-expanding Nitinol
frame with a high radial force that interacts withtissue a few millimeters below the aortic annulus,
where the left bundle branch emerges from the left
side of the ventricular septum (12). Mechanical
compression leading to temporary inﬂammation or
permanent damage in the conduction pathways is
probably the main determinant of CD. This mecha-
nism may be affected further by anatomic character-
istics such as the presence of extensive calcium
deposits (3) or by procedural steps such as crossing of
the aortic valve with a wire and valvuloplasty (13).
FACTORS ASSOCIATEDWITH PERMANENT PACEMAKER
IMPLANTATION RATE. In addition to the pre-operative
electrocardiographic and anatomic features that can
inﬂuence the occurrence of CD, it is important to
consider the impact of implantation technique.
Among several studies focused on the search for the
predictors of PPI, most identiﬁed implantation depth
as an independent predictor (14–17), whereas a few
did not conﬁrm this association (5,18). However,
these studies were mostly retrospective, were not
homogeneous in procedural technique, and included
small cohorts of patients. The importance of the cor-
rect implantation depth of the MCS was originally
highlighted by Piazza et al. (12), and recently Tchet-
che et al. (6) demonstrated that a high implantation
using the AccuTrak delivery system allowed for a
reduction in new PPI. The importance of implantation
FIGURE 4 Relationship Between Valve Size and Implant Depth
Larger valve sizes were associated with deeper implants (Cochran-Armitage trend test,
p ¼ 0.008).
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844depth to prevent LBBB was also described for
the balloon-expandable prosthesis by Urena (19).
The ADVANCE II study is a prospective observa-
tional study designed to examine the best possible
results by ensuring homogenous patient selection
and procedural technique. Although the mean im-
plantation depth in the overall population was close
to 6 mm (6.9  4.3 mm), in those patients in whom a
correct implantation was achieved, the mean depth
was 3.0  2.2 mm. This is comparable to that ob-
tained in the experience described by Tchetche et al.
(6). The importance of a shallow implantation depth
in limiting the need for PPI after TAVR was
conﬁrmed by the 4-mm cutoff value obtained in our
study. In particular, a depth shallower than 4 mm
was associated with a Kaplan-Meier rate of Class I/II
PPI of 6.1%.
The importance of implantation depth is also
highlighted by the tight association with CD at
30 days (Figure 3), both for AV and IV disturbances.
No signiﬁcant association was observed between CD
and either oversizing or post-dilation. This is at
variance with Schroeter et al. (20), who described a
relationship between CD onset and both oversizing
and use of larger diameter prostheses. In our experi-
ence, oversizing was calculated based on the nominal
perimeter of the MCS and not on a direct measure
after implantation and was observed in only 10.9% of
patients. Importantly, prosthesis size was decided
according to pre-operative MSCT measurements in
89.7% of patients and not on TTE measurements as in
previous studies (21). In addition, in the ADVANCE II
study, all 4 valve sizes were used, in contrast to the
majority of previous studies in which the 23-mm and
31-mm prostheses were seldom used. Interestingly, asvalve size increased, the probability of a low implant
depth increased (p ¼ 0.008), possibly related to the
wider frame design. This last observation could in
part explain the fact that optimal MCS implantation
was reached in only one-half of the population. The
depth of implantation with larger valves can be
partially controlled by careful manipulation of the
stiff wire in combination with controlled pacing (100
to 120 beats/min) during the ﬁrst third of deployment;
however, these maneuvers do not guarantee exact
positioning. The attempt to obtain optimal implan-
tation may explain the incidence of valve-in-valve
(2.1%) and embolization (5.7%) (Table 3).
In our experience post-dilation was not associated
with the occurrence of new CD; however, the limited
number of patients undergoing post-dilation in the
study (possibly because of the frequent use of
pre-dilation) does not allow generalization of this
ﬁnding.
Some of the baseline ECG parameters that were
previously described to predict new CD after TAVR,
including right bundle branch block, left anterior
hemiblock, and atrial ﬁbrillation were not associated
with PPI on multivariable analysis. This may be a
result of patient selection bias, as normal baseline
ECG was preferred to facilitate the interpretation of
new-onset CD.
INDICATIONS FOR NEW PERMANENT PACEMAKERS.
In the design of the ADVANCE II study, adherence to
the 2007 ESC guidelines on pacing was recommended,
which is in contrast to previous studies that either did
not specify the indications (17) or used prophylactic
pacing in patients with new LBBB and prolonged PR
interval (3,22). In our study, all new PPI but 1 were
implanted during the index hospital stay, and no
adverse events related to CD were observed at
30 days. In addition, no total AV block or sudden
death occurred between discharge and 30 days. A
reason for very early or prophylactic PPI may be the
push for early discharge for economic reasons,
favored by the decrease in procedural complications
in recent years. However, the expansion of TAVR
to lower risk and younger patients in the future will
require a careful approach to PPI. Thygesen et al. (23)
recently demonstrated in a retrospective analysis a
reduction in PPI from 27.4% to 19.7% simply by reas-
sessing indications to PPI. Accordingly, our rigorous
pacing policy resulted in a PPI rate of 18.2%, which is
similar to the rate reported in the most recent ran-
domized TAVR trial (1) and reached 13.3% in patients
with correct implantation. Absence of rigorous criteria
explain the different incidence of new PPI in the
CHOICE (A Comparison of Transcatheter Heart Valves
PERSPECTIVES
WHAT IS KNOWN? The rates of new PPI and their indications
in TAVR, especially with self-expanding devices, vary widely.
WHAT IS NEW? In this study, optimal deployment with high
implant depth as well as strict adherence to international
guidelines on the management of conduction disturbances
resulted in a lower rate of PPI. In this set-up, there is a negligible
risk of adverse events after hospital discharge.
WHAT IS NEXT? New device designs, including repositionable
systems, will allow for better control of device positioning
within the landing zone and might further improve the rate
of PPI.
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845in High Risk Patients With Severe Aortic Stenosis) trial
(24) that may have led to a high rate not only for MCS
prosthesis (37.6%) but also for Sapien XT device,
where it reached 17.3%.
TIMING AND RESOLUTION OF CONDUCTION
DISTURBANCES. A high rate of new AV and IV CD
was observed within the ﬁrst 48 h of TAVR, with a
signiﬁcant resolution by 30 days (Table 4). Specif-
ically, the rate of new LBBB and ﬁrst-degree AV block
had decreased by 43.2% and 73.9%, respectively
(Figure 2), in agreement with previous observations
(14,19,25) and similar to the recent data from the
PARTNER (The PARTNER trial: Placement of Aortic
Transcatheter Valve Trial) (26) on LBBB where 57.9%
of the new-onset LBBB resolved at 30 days after
balloon-expandable valve implantation. The tran-
sient nature of these CD can be explained in part by
the temporary inﬂammation caused by the mechani-
cal trauma occurring during the various steps of the
TAVR procedure (13). This ﬁnding supports the
importance of avoiding a liberal use of early PPI after
TAVR. In particular, the occurrence of a new LBBB
in a patient with a normal baseline ECG should not be
an indication for pacing. Investigation of the sub-
Hisian conduction with an electrophysiologic study
in patients with new LBBB and very long PR interval
(>300 ms), especially when these CD persist for over
72 h, may be advocated.
Finally, we observed a signiﬁcant increase in the
rate of available intrinsic rhythm at 30 days, together
with a trend of reduced ventricular pacing time.
Therefore, even with a conservative pacing policy as
in our study, some implants prove unnecessary in the
short term, in agreement with recent ﬁndings (23).
STUDY LIMITATIONS. This study describes conduc-
tion disturbances and new PPI after MCS implantation
with pre-deﬁned indications in a relatively small
population. The low baseline prevalence of atrial
ﬁbrillation (10.5%) and pre-operative AV (24.2%) and
IV (23.2%) CD should be considered a potential selec-
tion bias that could have reduced the incidence of PPI
and prevented generalization of the results. Patients
with persistent and permanent atrial ﬁbrillation were
excluded to reduce ambiguous or unfeasible inter-
pretation of CD following TAVR. The lack of ambula-
tory ECG monitoring in the follow-up analysis should
be taken in account in the evaluation of CD resolution
at 7 and 30 days.
Although the study included 9 sites very experi-
enced in MCS implantation, optimal implant depth
was only achieved in 43.2% of the patients. At the
moment, the new PPI rate of 13.3% may be thebest result achievable with the present device and
delivery system.
CONCLUSIONS
CD are multifactorial events occurring after both
surgical valve replacement and TAVR that should be
monitored and properly treated. The tendency to-
ward CD resolution after TAVR and the rarity of late-
onset complete AV block support a conservative
approach to PPI that is driven by international
guidelines. For this reason, it appears mandatory to
avoid the practice of unnecessary or prophylactic
pacemaker implantation. The best results can be ob-
tained with a careful, high implantation of the MCS
prosthesis; however, in this study, the optimal
implant depth was achieved in less than 50% of pa-
tients. It is likely that newer generation devices that
are repositionable and recapturable will improve the
ability to properly position the device. This may lead
to reduced rates of PPI, which is of key importance as
the use of TAVR in lower-risk and younger patients is
under consideration.
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